

# #T1D CGM Accessforall



On average people with T1D in Aotearoa NZ will lose 22 years<sup>1</sup> of healthy life.

Lifesaving and life-changing technologies to measure blood glucose and deliver insulin in response to need, are the foundation of type 1 diabetes (T1D) treatment and care in the 21st century, supporting people living with T1D and their whānau to thrive.



But in Aotearoa, New Zealand funded access to these technologies lags behind the rest of the OECD including Australia, the UK and Canada.

This needs to change. The #T1D CGM Accessforall campaign aims to make diabetes technologies an affordable and accessible option for everyone with T1D.

The first step is funding for continuous glucose monitors (CGM and Flash GM).

In the lead up to the NZ general election on 14th October 2023, the NZ T1D community are aiming to persuade all sides of politics to commit to providing increased access to these technologies as a basic standard of care for the approximately 20,000 New Zealanders with T1D. This would help address the social and health inequities in Aotearoa caused by lack of funding and access for people living with T1D.

This means an investment of \$26m per year<sup>2</sup> to support funded access for CGMs, with a return of \$82m p.a in economic productivity.

1. T1D Index, <https://www.t1dindex.org/>  
2. Note: this excludes complication costs.

## Why this approach?

Providing funding for CGMs, alongside pumps, will deliver extensive savings for the NZ health system in three key categories:



Short term savings relating to reduced hospital and healthcare costs because of fewer incidences of severe hypoglycemia



Long term savings from reduced rates of diabetes related complications



Reduced costs of consumables for manual blood glucose measurement (test strips)

CGM and pumps are proven to help with blood sugar levels, reducing the likelihood of dangerous highs and lows in the short term and of costly and damaging complications in the longer term.

We need urgent funding to allow people with T1D access to this life saving technology, rather than restrict it to those who can afford it. Increased availability and access, a change of focus to what is best for the patient, not what the pocket can afford and tackles the greatest barrier to health equity for children and adults living with T1D in Aotearoa, New Zealand.

**This election, let's ask our MPs to give Pharmac clear direction (and funding) for CGMs.**



“

“T1D runs my life and I'd like to be able to take back some of that control.”

– Morgan

“

“I am a type 1 and CGMs make life so much easier. Just think how much money will be saved if we prevent long-term side effects.”

– Jeamien

“

“I am a type 1 solo mum of 4. These expensive and life-saving CGMs would change my whole family's life. My brain is so exhausted trying to manually be a pancreas.”

– Nikki

We should fund a technology that massively improves quality of life, reduces cost on the health care system and is good for people with T1D, their whānau and all of Aotearoa, New Zealand.

For more information email Sandra at [sbraithwaite@jdrf.org.nz](mailto:sbraithwaite@jdrf.org.nz)